Cellectar Biosciences, Inc. Resources

Patients News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Platform
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • Iopofosine
  • Clinical Studies
    • Overview
    • Waldenstrom’s Macroglobulinemia Phase 2 Study Active, not recruiting
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Study Active, not recruiting
    • Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG Active, not recruiting
  • Patients
  • News & Media
  • Investors
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Cellectar Biosciences Receives Japanese Patent for CLR 131 and CLR 125 for the Treatment of Cancer Stem Cells

Apr 18, 2017

Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer

Apr 12, 2017

Cellectar Biosciences Adds Industry Veterans Douglas Swirsky and Frederick Driscoll to Its Board of Directors

Apr 10, 2017

After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers

Mar 30, 2017

Cellectar Biosciences Further Deepens Intellectual Property Portfolio with Patent Grant for PET Imaging PDC

Mar 21, 2017

Cellectar Biosciences Reports 2016 Company Performance and Continued Progress in First Quarter 2017

Mar 15, 2017

Newly Issued Japanese Patent For PDC Optical Agents Further Strengthens Cellectar Biosciences’ Intellectual Property Portfolio

Mar 14, 2017

Cellectar Biosciences to Host Conference Call on March 15 to Report Fourth Quarter and Year-End 2016 Financial Results and Corporate Performance

Mar 9, 2017

Expanding Its Strategic Relationship with Wisconsin Alumni Research Foundation (WARF), Cellectar Biosciences Executes New License Agreement

Mar 8, 2017

Cellectar Biosciences to Present at 29th Annual Roth Conference

Mar 6, 2017
    • 1...
    • 20
    • 21
    • 22
    • 23
    • 24
    • 25
    • 26
    • 27
    • 28
    • 29
    • ...36
    © 2025 Cellectar Biosciences, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Q&A